| Primary |
| Prostate Cancer |
74.8% |
| Product Used For Unknown Indication |
11.8% |
| Prostate Cancer Metastatic |
8.7% |
| Glaucoma |
1.2% |
| Hypertension |
0.6% |
| Metastasis |
0.6% |
| Neoplasm Prostate |
0.6% |
| Drug Use For Unknown Indication |
0.3% |
| Hyperuricaemia |
0.3% |
| Metastases To Prostate |
0.3% |
| Neoplasm Malignant |
0.3% |
| Reflux Oesophagitis |
0.3% |
|
| Injection Site Pain |
15.4% |
| Injection Site Swelling |
8.1% |
| Injection Site Erythema |
7.3% |
| Abdominal Pain |
5.7% |
| Hot Flush |
5.7% |
| Injection Site Warmth |
5.7% |
| Fatigue |
4.9% |
| Nausea |
4.9% |
| Pain |
4.9% |
| Prostatic Specific Antigen Increased |
4.9% |
| Injection Site Abscess |
4.1% |
| Injection Site Nodule |
4.1% |
| Injection Site Reaction |
4.1% |
| Asthenia |
3.3% |
| Cardiac Arrest |
3.3% |
| Death |
3.3% |
| Hyperhidrosis |
3.3% |
| Anaemia |
2.4% |
| Depression |
2.4% |
| Drug Ineffective |
2.4% |
|
| Secondary |
| Prostate Cancer |
57.6% |
| Prostate Cancer Metastatic |
14.1% |
| Product Used For Unknown Indication |
7.1% |
| Calculus Urinary |
4.0% |
| Hypocitraturia |
4.0% |
| Nausea |
4.0% |
| Pain |
4.0% |
| Vomiting |
4.0% |
| Abdominal Pain |
1.0% |
|
| Chest Discomfort |
18.8% |
| Metastases To Lymph Nodes |
12.5% |
| Wheezing |
12.5% |
| Drug Ineffective |
9.4% |
| Intentional Drug Misuse |
9.4% |
| Drug Administration Error |
3.1% |
| Hyperhidrosis |
3.1% |
| Injection Site Oedema |
3.1% |
| Medication Error |
3.1% |
| Pleural Effusion |
3.1% |
| Pruritus |
3.1% |
| Puncture Site Haemorrhage |
3.1% |
| Swelling |
3.1% |
| Unresponsive To Stimuli |
3.1% |
| Urinary Tract Infection |
3.1% |
| Urticaria |
3.1% |
| Vomiting |
3.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
25.2% |
| Metastases To Bone |
17.0% |
| Prostate Cancer |
13.8% |
| Prostate Cancer Metastatic |
10.4% |
| Pain Management |
8.7% |
| Abdominal Pain |
2.9% |
| Cancer Pain |
2.9% |
| Hormone Therapy |
2.9% |
| Pain |
2.9% |
| Blood Pressure Increased |
1.9% |
| Neoplasm Prophylaxis |
1.9% |
| Stasis Dermatitis |
1.9% |
| Arthralgia |
1.0% |
| Blood Calcium Decreased |
1.0% |
| Blood Cholesterol Increased |
1.0% |
| Constipation |
1.0% |
| Medical Diet |
1.0% |
| Unevaluable Event |
1.0% |
| Prophylaxis |
0.7% |
| Pulmonary Embolism |
0.7% |
|
| Hypoacusis |
19.5% |
| Renal Failure Acute |
14.6% |
| Blood Alkaline Phosphatase Increased |
12.2% |
| Polyneuropathy |
9.8% |
| Pulmonary Oedema |
4.9% |
| Thrombocytopenia |
4.9% |
| Angioedema |
2.4% |
| Bone Pain |
2.4% |
| Cerebral Infarction |
2.4% |
| Chest Discomfort |
2.4% |
| Diabetes Mellitus |
2.4% |
| Hemiplegia |
2.4% |
| Hypercholesterolaemia |
2.4% |
| Hypophosphataemia |
2.4% |
| International Normalised Ratio Increased |
2.4% |
| Long Qt Syndrome |
2.4% |
| Musculoskeletal Discomfort |
2.4% |
| Myelodysplastic Syndrome |
2.4% |
| Nephrotic Syndrome |
2.4% |
| Pain In Extremity |
2.4% |
|
